Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer (HCH003)

This study has been terminated.
(Principal Investigator has left institution. IND withdrawn.)
Sponsor:
Information provided by (Responsible Party):
Madeline O'Connor, Holy Cross Hospital, Florida
ClinicalTrials.gov Identifier:
NCT01090830
First received: March 22, 2010
Last updated: March 19, 2013
Last verified: March 2013
  Purpose

The purpose of this study is to establish the safest dose of the investigational medication Belinostat that can be administered with a standard of care chemotherapy regimen of bevacizumab, carboplatin, and paclitaxel. Further study will examine the short and long-term effect (up to 2 years) of this medication on participant's disease status and overall survival.


Condition Intervention Phase
Non-Small-Cell Lung Carcinoma
Drug: Belinostat, carboplatin, paclitaxel and bevacizumab
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Phase Ib/II Study to Determine the Recommended Dose, Safety, and Preliminary Efficacy of Belinostat When Used in Combination With Carboplatin, Paclitaxel, and Bevacizumab in Patients With Untreated Non-small Cell Lung Cancer.

Resource links provided by NLM:


Further study details as provided by Holy Cross Hospital, Florida:

Primary Outcome Measures:
  • The recommended phase II dose of Belinostat when used in combination with carboplatin, paclitaxel and bevacizumab. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    The aim of the initial phase Ib component is to establish the maximum tolerated dose (MTD) of Belinostat when used with a standard of care carboplatin, paclitaxel and bevacizumab course of therapy ("BelCap-B") regimen. The MTD will be determined through the process of dose-limiting-toxicity evaluation.


Secondary Outcome Measures:
  • To evaluate overall survival with this investigational treatment. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    The percentage of participants who are alive at 2 years post initiation of investigational treatment.

  • Long-term safety (late-effects up to 2 years) [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Long-term (up to 2 years) safety evaluation of the investigational treatment will be evaluated by ongoing evaluation of adverse events/late-effects using the NCI Common Toxicity Criteria.

  • Evaluate disease response of participants who receive this investigational medication regimen [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Response to therapy will be measured by the RECIST criteria. The investigators will assess the percentage of research participants whose disease status indicates a response to investigational treatment according to the RECIST criteria.

  • To evaluate progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    The number (%) of participants who do not show evidence of disease progression (according to RECIST criteria)at 2 years post initial administration of the investigational product.


Enrollment: 7
Study Start Date: April 2010
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Belinostat
This is a one arm, open label study of the investigational medication Belinostat.
Drug: Belinostat, carboplatin, paclitaxel and bevacizumab

Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.

In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles.

Other Names:
  • Belionostat
  • PDX101
  • Bevacizumab
  • Carboplatin
  • Paraplatin
  • Paclitaxel
  • Taxol

Detailed Description:

This is a Phase Ib/II, single center, open label, dose-finding study to evaluate the use of Belinostat when given with standard of care chemotherapy in patients with untreated, non-small cell lung cancer (NSCLC). In the Phase Ib portion, dose limiting toxicity evaluation will be used to determine the maximum tolerated dose (MTD) of Belinostat when given with fixed doses of bevacizumab, carboplatin, and paclitaxel(a BelCap-B regimen). Three dose levels of Belinostat are proposed (600mg/kg, 800mg/kg, 1000mg/kg). Determination of MTD will be the basis for establishing set dosing for the phase II component of the study.

The phase II portion of the study includes further drug safety evaluation and a preliminary assessment of efficacy of Belinostat when used with specified induction and maintenance regimens. Response will be evaluated through the RECIST criteria. Additional analysis will be done to estimate the time to response, progression free survival, median survival, and overall survival (OS) in study participants to 2 years post-initiation of cycle 1.

Based on a standard 3 x 3 statistical design, the phase Ib portion may accrue between 3 to 12 participants. Phase II will have a minimum sample size of 10 and a maximum of 16 patients. Participants who complete the Phase I portion and are able to advance to Phase II, will be evaluable for the Phase II objectives.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically documented NSCLC confirmed.
  • Has advanced NSCLC (Stage IV), not previously treated with any chemotherapy regiment (prior adjuvant chemotherapy and/or chemotherapy/radiation for Stage III allowed).
  • Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan.
  • Life expectancy of > 3 months
  • Must have returned to baseline or grade 1 adverse event from any acute toxicity related to prior therapy
  • Adequate immune and multisystem organ function (as evidenced by urine and blood values within specified parameters).

Exclusion Criteria:

  • Brain or meningeal metastases. Note, patients with adequately treated brain metastases, e.g. surgically resected, or adequately controlled by radiotherapy, with no residual neurological symptoms due to metastases and no steroid treatment required, can be enrolled. If clinical suspicion, adequate investigations should be performed to rule out brain metastases or meningeal involvement.
  • History of a previous malignancy within 5 years with the exception of non-metastatic non-melanoma skin cancer or cervical carcinoma in situ. Prior systemic therapy for other malignancy must be completed at least 5 years before treatment is allowed.
  • Lung carcinoma of squamous cell histology (mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible; sputum cytology alone is not acceptable).
  • History of hemoptysis within 3 months prior to enrollment
  • Current or recent (within 10 days of enrollment) use of aspirin (>325 mg/day) or chronic use of other non-steroidal anti-inflammatory medications.
  • Prior systemic anti-tumor therapy for Stage IV lung cancer. Note, prior radiotherapy is allowed provided treatment was completed at least 2 weeks before enrollment. Prior surgery is allowed if completed at least 4 weeks before enrollment.
  • Treatment with investigational agents within the 2 weeks prior to enrollment.
  • Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease.
  • Hypertension not controlled by medical therapy.
  • Significant cardiovascular disease, myocardial infarction within the past 6 months, unstable angina, unstable arrhythmia or a need for anti-arrhythmic therapy (use of medication to control heart rate in patients with atrial fibrillation is allowed, if stable medication for at least last month prior to enrollment, or evidence of acute ischemia on electrocardiogram).
  • Marked baseline prolongation of QT/QTc interval that required use of concomitant medication that may cause Torsade de Pointes
  • Significant, non-healing wounds, acute or non-healing ulcers, or bone fractures within 3 months of fracture.
  • Undergone major surgery within 4 weeks of planned initiation of cycle 1.
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of enrollment.
  • History of any gastrointestinal bleeding within the 3 months prior to enrollment.
  • Known hypersensitivity to either platinum compounds or paclitaxel, or any components of the study medications, and inability for desensitization.
  • Peripheral neuropathy NCI ≥ Grade 2.
  • Co-existing active severe infection or any co-existing medical condition likely to interfere with trial procedures.
  • Known infection with HIV, or known active Hepatitis B or C infection.
  • Pregnant or lactating.
  • not willing to use effective contraception during the study and until 6 months post-completion of last cycle administered
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01090830

Locations
United States, Florida
Holy Cross Hospital, Inc
Fort Lauderdale, Florida, United States, 33308
Sponsors and Collaborators
Holy Cross Hospital, Florida
Investigators
Principal Investigator: Martin E Guiterrez, MD Holy Cross Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: Madeline O'Connor, Executive Director of Clinical Research, Holy Cross Hospital, Florida
ClinicalTrials.gov Identifier: NCT01090830     History of Changes
Other Study ID Numbers: HCH003
Study First Received: March 22, 2010
Last Updated: March 19, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Holy Cross Hospital, Florida:
Non small cell lung cancer
Belinostat
carboplatin
Paclitaxel
Bevacizumab
chemotherapy
Maximum Tolerated Dose
Neoplasms, Pulmonary
Lung Cancer
Event Free Survival
Disease free survival
Progression Free Survival
Histone Deacetylase Inhibitors
Treatment Efficacy

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Bevacizumab
Carboplatin
Paclitaxel
Histone Deacetylase Inhibitors
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors

ClinicalTrials.gov processed this record on April 21, 2014